Marth, C. 2017. Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial:  . Cancer Breaking News. 5, 2 (Aug. 2017), 3–4. DOI:https://doi.org/10.19156/cbn.2017.0041.